Aranapakam Mudumbai Venkatesan

This inventor holds 83 USPTO granted patents and 12 published patent applications, plus 5 CIPO patents and 9 EPO patents, primarily in Cancer Therapeutics (CPC class A61K31-444). Top assignees: American Cyanamid Company, Asana Biosciences, LLC, Wyeth. Active years: 1994-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Aranapakam Mudumbai Venkatesan. Retrieved from https://idiyas.com/inventor/aranapakam-mudumbai-venkatesan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 83 (Patent Applications = 12)

% Patents Active = 73.5

CIPO Patents = 5 (Patent Applications = 15)

EPO Patents = 9 (Patent Applications = 12)

Average Co-Inventor Count = 3.5

ph-index = 13

Forward Citations = 546(Granted Patents)

Forward Citations (Not Self Cited) = 505(Dec 10, 2025)

Inventors with similar research interests:

Location History:

New York, NY (US) (1997)
Elmhurst, NY (US) (1994 - 1998)
Queens County, NY (US) (1998)
Rekgo Park, NY (US) (2002 - 2004)
Malvern, PA (US) (2014 - 2017)
Chadds Ford, PA (US) (2014 - 2023)
Rego Park, NY (US) (1995 - 2024)

Company Filing History:

29 out of 3,580

American Cyanamid Company

patents

16 out of 34

Asana Biosciences, LLC

American Home Products Corporation

patents

5. 4 out of 113

Wyeth Holdings Corporation

patents

6. 2 out of 3

Curadev Pharma Pvt Ltd

patents

7. 2 out of 2

Elucida Oncology, Inc.

Abs Development 1, Inc.

patent

10. 1 out of 1

Ansana Biosciences, LLC

patent

11. 1 out of 1

Asan Biosciences, LLC

patent

12. 1 out of 32

Endo Pharmaceuticals Inc.

patents

13. 1 out of 834,601

Other

patents

Years Active: 1994-2024

Loading Chart...

Areas of Expertise:

Folate Receptor

Nanoparticle Drug Conjugates

Heterocyclic Inhibitors

ERK1 Inhibitors

ERK2 Inhibitors

Kynurenine Pathway

Triazine Compounds

PI3 Kinase

mTOR Inhibitors

Pyrimidine Derivatives

Beta-Lactamase Inhibitors

Depression Treatments

83 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11957760 - Folate receptor targeted nanoparticle drug conjugates and uses thereof (2024-04-16),

2. 11925629 - Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer (2024-03-12),

3. 11744897 - Folate receptor targeted nanoparticle drug conjugates and uses thereof (2023-09-05),

4. 11685736 - P2Xand/or P2Xcompounds and methods (2023-06-27),

5. 11103491 - Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer (2021-08-31),

6. 10751332 - Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer (2020-08-25),

7. 10647720 - Pyrimido-pyridazinone compounds and methods of use thereof (2020-05-12),

8. 10590127 - P2Xand/or P2Xcompounds and methods (2020-03-17),

9. 10544145 - P2Xand/or P2Xcompounds and methods (2020-01-28),

10. 10471051 - Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer (2019-11-12),

11. 10316039 - [object Object] (2019-06-11),

12. 10294212 - Inhibitors of the kynurenine pathway (2019-05-21),

13. 10183944 - Pyrimido-pyridazinone compounds and methods of use thereof (2019-01-22),

14. 10022381 - Triazine compounds as PI3 kinase and mTOR inhibitors (2018-07-17),

15. 9944637 - [object Object] (2018-04-17),

Title: Aranapakam Mudumbai Venkatesan: Pioneering Cancer Treatment Innovations

Introduction:

Aranapakam Mudumbai Venkatesan, a visionary inventor based in Rego Park, NY, has made significant contributions to the field of medicine with 81 patents to his name. His latest patents showcase his expertise in developing advanced cancer treatment solutions using nanoparticle drug conjugates and innovative compounds targeting P2Xand/or P2Xreceptors.

Latest Patents:

Venkatesan's groundbreaking patents include the development of Folate Receptor Targeted Nanoparticle Drug Conjugates, offering a promising approach to treating cancer by utilizing ultrasmall nanoparticles and folate receptor targeting ligands. Additionally, his work on novel P2Xand/or P2Xcompounds presents new methods for regulating these receptors, with potential applications in pain management for patients.

Career Highlights:

Throughout his illustrious career, Venkatesan has lent his expertise to renowned companies such as American Cyanamid Company and Asana Biosciences, LLC. His innovative approach to research and development has led to transformative discoveries in the field of pharmaceuticals, earning him recognition as a key player in the industry.

Collaborations:

Collaborating with esteemed colleagues like Jeremy Ian Levin and Roger Astbury Smith, Venkatesan has fostered a dynamic environment of innovation and knowledge sharing. Together, they have worked towards pushing the boundaries of medical science, paving the way for groundbreaking discoveries and advancements in cancer treatment.

Conclusion:

Aranapakam Mudumbai Venkatesan's relentless pursuit of excellence and unwavering dedication to advancements in cancer treatment have positioned him as a trailblazing figure in the field of medicine. His patents stand as testaments to his ingenuity, promising a brighter future for patients in need of innovative therapeutic solutions.

Profile summary based on public USPTO records.